Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer

Keyphrases

• Lung Cancer 100%
• Mouse Model 100%
• Epidermal Growth Factor Receptor Inhibitors 100%
• Gefitinib 100%
• Epidermal Growth Factor Receptor 36%
• Inhibition Rate 18%
• Mutant Mice 18%
• Highly Effective 18%
• Chemopreventive 18%
• Tumor multiplicity 18%
• Lung Carcinogenesis 18%
• Tumor Load 18%
• P53 mutant 18%
• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 9%
• Lung 9%
• Expression Level 9%
• Cell Proliferation 9%
• Immune Response 9%
• Chemotherapy 9%
• Apoptosis 9%
• DNA Synthesis 9%
• Tyrosine Kinase Inhibitor 9%
• Angiogenesis 9%
• High Affinity 9%
• Clinical Application 9%
• Cell Migration 9%
• Treatment Group 9%
• Carcinogen 9%
• Monotherapy 9%
• KRAS mutation 9%
• K-ras 9%
• Oligonucleotide Array 9%
• Cell Transformation 9%
• Lung Tumor 9%
• Lung Tumorigenesis 9%
• Individual Animal 9%
• Preinvasive Lesions 9%
• Chemotherapeutic Activity 9%
• Iressa 9%
• ZD1839 9%
• Delayed Administration 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Lung Cancer 100%
• Mouse Model 100%
• Epidermal Growth Factor Receptor Kinase Inhibitor 100%
• Gefitinib 100%
• Neoplasm 30%
• Epidermal Growth Factor Receptor 30%
• Protein P53 15%
• Mouse Mutant 15%
• Lung Carcinogenesis 15%
• Chemotherapy 7%
• Protein Tyrosine Kinase Inhibitor 7%
• Treatment Group 7%
• Carcinogenesis 7%
• Carcinogen 7%
• Monotherapy 7%
• Non Small Cell Lung Cancer 7%
• Oligonucleotide 7%
• Lung Tumor 7%
• Chemopreventive Agents 7%